Asset 1

Myeloid and Erythroid Hematotoxicity Colony Forming Cell (CFC)
Assay Services

Predict neutropenia and severe anemia at the preclinical drug development stage.

Discovery’s Gentest® Myeloid and Erythroid CFC Assay Services help you predict neutropenia or severe anemia ahead of clinical trials.

These in vitro assays replicate in vivo cell biology conditions. We incubate primary bone marrow cells with your test drugs in a semi-solid, methylcellulose-based medium containing growth factors and count the resulting hematopoietic progenitor-derived colonies. We then provide you with a detailed report, including data on changes to the expected number of cell colonies in your drug’s presence.

CFU-GM: Colony-Forming Unit-Granulocyte Macrophage

BFU-E: Burst-Forming Unit-Erythroid

IND-Enabling Myeloid and Erythroid CFC Assays Performed by Blood Cell Biology Experts

Clinical Correlation and Multi-Species Data

Correlation between CFU-GM IC50 values and grade III/IV neutropenia

Comparative IC50 values between species

Experts in Cell-Based Assays, Predictive Hematotoxicity,
and Drug Screening Services.

Discovery’s expert cell biologists have developed numerous novel assays, enabling us to offer a broader and more strategic array of services to our clients. Our ongoing innovations accelerate drug discovery and development, ultimately enhancing patient outcomes.

Featured Scientist - Dr. Emer Clarke, VP, Cell Biology

Dr. Clarke has over 25 years of experience in stem cell biology, spanning both clinical and industrial settings. She plays a pivotal role in driving innovations and managing Discovery’s scientific operations, including research and development and client services. Dr. Clarke is also actively involved in client affairs, offering one-on-one consultations, study design, and data analysis.

Featured Resources

Hematopietic Colony Forming Cell (CFC) Assay

The preclinical screening method that helps clients eliminate bad players earlier in the drug development process. White Paper

USE Predicting Thrombocytopenia

Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co treatment with nicotinic acid. Publication

Contact Us Today

Quick Links


Development and Clinical
Trial Solutions